为什么德国医疗技术交易质量体系优先？
德国医疗器械、诊断、精密医疗制造和医疗软件企业可为中国买方提供高质量产品和工业能力。但医疗技术交易如果监管或质量体系存在缺陷，估值基础会迅速改变。
买方应先确认产品是否能够持续销售。
估值重点
买方应关注监管状态、质量体系、临床证据、毛利率、渠道、知识产权、产品生命周期、研发管线和团队留任。
尽职调查重点
尽调应覆盖技术文件、MDR路径、质量体系、召回和投诉、经销商合同、产品责任保险、知识产权、数据合规和税务。
Lyndon如何协助
Lyndon可协助中国买方、德国医疗技术企业和顾问准备估值、资料室、监管风险清单和交易执行。
About the Author
Daniel Bae
Co-founder & CEO, Lyndon Advisory
Daniel is an investment banker with 15+ years of experience in M&A, having advised on deals worth over US$30 billion. His career spans Citi, Moelis, Nomura, and ANZ across London, Hong Kong, and Sydney. He holds a combined Commerce/Law degree from the University of New South Wales. Daniel founded Lyndon Advisory to solve the pain points in M&A, enabling bankers to focus on what matters most — delivering trusted advice to clients.
About Lyndon Advisory
Lyndon Advisory is an M&A advisory firm built for Asia Pacific. We help business owners sell their companies and investors make strategic acquisitions with senior-led execution, disciplined process management, and AI-supported buyer intelligence.
Learn about selling your business